CCRA AGM Roundup 2017

Housed within the dramatic and suitably clinical-feeling Miller Insurance offices near Aldgate in London, a gathering of great clinical minds occurred for the CCRA AGM. Professor Atholl Johnston, President, opened up the day with introductions before we launched into 5 presentations back-to-back. Firstly we heard from Andy Catton, a Partner at Miller Insurance, on specialist

Continue Reading

Ipsen and Exelixis’s treatment for liver cancer, Cabometyx, sees positive Phase III trial results

Ipsen’s collaboration with Exelixis is on track to file cancer treatment, Cabometyx, for a new liver cancer indication in the first half of next year, following positive Phase III trial results. The randomised, double-blind CELESTIAL study was set up to test Cabometyx in 760 patients who have advanced hepatocellular carcinoma (HCC), which is the sixth

Continue Reading

Clinical Professionals’ Divisional Director Runs the Royal Park Half Marathon for Bloodwise

Suzanne Swan, Divisional Director at the Clinical Professionals Group, completed on Sunday Bloodwise’s Royal Park Half Marathon in 2hrs 11mins and 55 seconds. We are extremely proud to announce that her efforts raised over £700 in aid of the charity, which more than doubled her initial target of £300. Bloodwise, formerly known as Leukaemia and

Continue Reading

Bloodwise funded clinical trial identifies genetic fault in leukaemia patients that affects response to treatment

A recently conducted clinical trial has found a genetic fault that has been identified in people with an aggressive type of leukaemia that notably affects how the patient responds to treatment. Findings from a clinical trial conducted by University of Birmingham examined whether survival times for those with acute myeloid leukaemia (AML) or myelodysplastic syndrome

Continue Reading